Literature DB >> 33880882

Optimized Photoactivatable Lipid Nanoparticles Enable Red Light Triggered Drug Release.

Nisha Chander1, Johannes Morstein2, Jan S Bolten3, Andrej Shemet2, Pieter R Cullis1,4, Dirk Trauner2, Dominik Witzigmann1,4.   

Abstract

Encapsulation of small molecule drugs in long-circulating lipid nanoparticles (LNPs) can reduce toxic side effects and enhance accumulation at tumor sites. A fundamental problem, however, is the slow release of encapsulated drugs from these liposomal systems at the disease site resulting in limited therapeutic benefit. Methods to trigger release at specific sites are highly warranted. Here, it is demonstrated that incorporation of ultraviolet (UV-A) or red-light photoswitchable-phosphatidylcholine analogs (AzoPC and redAzoPC) in conventional LNPs generates photoactivatable LNPs (paLNPs) having comparable structural integrity, drug loading capacity, and size distribution to the parent DSPC-cholesterol liposomes. It is shown that 65-70% drug release (doxorubicin) can be induced from these systems by irradiation with pulsed light based on trans-to-cis azobenzene isomerization. In vitro it is confirmed that paLNPs are non-toxic in the dark but convey cytotoxicity upon irradiation in a human cancer cell line. In vivo studies in zebrafish embryos demonstrate prolonged blood circulation and extravasation of paLNPs comparable to clinically approved formulations, with enhanced drug release following irradiation with pulsed light. Conclusively, paLNPs closely mimic the properties of clinically approved LNPs with the added benefit of light-induced drug release making them promising candidates for clinical development.
© 2021 Wiley-VCH GmbH.

Entities:  

Keywords:  cancer; doxorubicin; liposome; photoswitch; triggered drug release

Mesh:

Substances:

Year:  2021        PMID: 33880882     DOI: 10.1002/smll.202008198

Source DB:  PubMed          Journal:  Small        ISSN: 1613-6810            Impact factor:   13.281


  1 in total

1.  Protein Binding Nanoparticles as an Integrated Platform for Cancer Diagnosis and Treatment.

Authors:  Xuemei Wang; Shengbo Li; Siqi Wang; Shuo Zheng; Zhenbing Chen; Heng Song
Journal:  Adv Sci (Weinh)       Date:  2022-08-18       Impact factor: 17.521

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.